News

As deucravacitinib surpasses its 1-year milestone since approval, clinicians continue to monitor its real-world performance among patients.

This Alopecia Awareness Month, we want to know your thoughts on necessary action points to improve alopecia awareness. Click here to answer this week's poll.

Stress from dermatologic conditions can create or magnify psychiatric illness.

Keep up with the latest headlines in dermatology from the past week, including awareness efforts following singer Jimmy Buffett's death from complications of Merkel cell carcinoma, AI dermatology tools lacking representation of darker skin tones, and more.

ICYMI, this week we had articles about acne vulgaris management from an expert panel, a look back at summer dermatology conferences, long-term results of roflumilast cream 0.15% for AD, and more.

Second-line end points of the TRICOTEL trial assessing atezolizumab plus vemurafenib and cobimetinib in melanoma with central nervous system metastases appear consistent with primary efficacy end points.

The physician-owned practice combines residency and Mohs fellowship programs with patient care.

This week’s collection of the latest dermatologic studies covers the hair regrowth cycle in mice, considering large language models in dermatology, cutaneous leiomyosarcomas subtypes, and the efficacy of tralokinumab in older adults with atopic dermatitis.

Topical minoxidil combined with oral spironolactone significantly improved hair density.

The condition may present as a manifestation of pediatric rosacea.

Recipients of the IFundWomen grant kicked off crowdfunding campaigns to grow their businesses.

BTA treatment was both safe and effective in male and female patients, indicating its potential as a therapeutic strategy in treating Egyptian patients with AGA.

Significant improvement was shown in erythema and pruritis and patients reported high satisfaction.

A coprimary end point in the phase 3 LEAP-010 study will not be met.

Roflumilast maintained disease control when patients switched to twice-weekly dosing.

The review found that utilizing dupilumab to treat these patients with AD cost more than using baricitinib, although dupilumab was more effective.

As we approach National Eczema Week and National Eczema Month, take a look at the most influential atopic dermatitis research from the last decade.

Perifollicular infundibulo-isthmic lymphocytoplasmic infiltrates and fibrosis appeared in all patients, regardless of ethnicity.

Patients treated by rheumatologists were more often treated with tumor necrosis factor inhibitors.

Click here to answer this week's skin cancer poll.

A panel of 9 dermatologists met and created 5 statements regarding the role of ceramide-containing skin care products in reducing skin barrier dysfunction related to acne treatments.

The VIOLIN study examined the burden of disease, prevalence, and treatment of vitiligo in patients in France.

Melanoma cases were almost 10 times higher in high Human Development Index countries than in low.

In this week’s Pointers With Portela, the 208SkinDoc takes an in-depth look at Merkel cell carcinoma after Jimmy Buffett passed away from a 4-year battle with the rare form of skin cancer.

Dermatology Times is reflecting on this summer's dermatology conferences with a recap of our top 3 articles from Fall Clinical, Maui Derm, World Congress, SDPA, and SPD.

Two poster presentations at this year’s Society for Pediatric Dermatology Meeting delve into the psychological impact of the condition and a new option for management.

Click here to answer this week's acne poll.

Endocrine toxic effects were more likely than nonendocrine to become chronic and continue at last follow-up.

Researchers found no statistically significant difference between injection techniques.